

## Synthesis, and Biological Activities of Some Schiff Bases Derivatives

Raed Jasim Mohammed<sup>1</sup>, Hanan M. Ali<sup>2</sup>

<sup>1,2</sup>University of Basrah, Iraq



DOI : <https://doi.org/10.61796/ijmi.v3i1.412>



### Sections Info

#### Article history:

Submitted: October 17, 2025

Final Revised: October 31, 2025

Accepted: November 10, 2025

Published: November 17, 2025

#### Keywords:

Schiff base derivatives

MTT assay

Biomolecules

Azo derivatives

### ABSTRACT

**Objective:** This study aims to synthesize and evaluate the biological activities of four Schiff base compounds derived from the condensation of benzaldehyde and selected amine derivatives, with a focus on determining their anticancer, antibacterial, and antifungal potentials. **Method:** Four compounds—namely compound 1 [(E)-1-(4-chlorophenyl)-N-(6-methoxybenzo[d]thiazol-2-yl)methanimine], compound 2 [(E)-4-(((6-methoxybenzo[d]thiazol-2-yl)imino)methyl)phenol], compound 3 [(E)-5-((2-methylbenzylidene)amino)-2,3-dihydrophthalazine-1,4-dione], and compound 4 [(E)-5-((2-hydroxybenzylidene)amino)-2,3-dihydrophthalazine-1,4-dione]—were synthesized and subjected to in vitro screening. **Results:** Compound 1 exhibited the strongest anticancer activity, outperforming the other derivatives. Compounds 1 and 2 showed pronounced antibacterial effects against *Staphylococcus aureus*, while compound 4 demonstrated activity against *Escherichia coli*. Compounds 3 and 4 also displayed significant antifungal inhibition against *Candida albicans*. **Novelty:** The study identifies specific structure–activity relationships among newly synthesized Schiff bases, highlighting distinct bioactive profiles and offering promising lead compounds for future therapeutic development.

## INTRODUCTION

Schiff bases are compounds composed of carbon and nitrogen atoms, which alkyl or aryl substituents can be combined [1]. Last years, numerous reports have investigated Schiff bases with biological properties, such as antifungal, antibacterial, anticancer, etc. The main property of Schiff bases is high purity and yield [2], [3].

Schiff bases have long served as a source of inspiration for chemists and biochemists [4]. Schiff bases are utilized in a variety of applications, including catalytic processes, crystal engineering, photo- or chemo detectors in biological systems, and medicine [5]. The Schiff base derivatives are important because of their biological activities [6].

Many derivatives of Schiff bases are reported, and their merged together will resultant a sum of exceedingly suitable molecules with appropriate biological activities [7,8]. Schiff bases and their derivatives, can inhibit cancer cells and induce cell death, requiring further investigation to determine their potential [9], [11].

The availability of pharmacophore fragments and a biodegradable and non-toxic Schiff bases allows for the creation of drugs carriers with their own potential pharmacological, opening up new avenues for further inquiry [12]. Herein, seek to prepare Schiff bases derivatives with perspective significance of biological properties.

## RESEARCH METHOD

All of the chemical materials supplied from Sigma Aldrich (99.8%). Deuterated solvents and tetramethylsilane (TMS) as an internal standard. The chemical shifts were measured in ( $\delta$ ) ppm using a Bruker DRX-500 spectrometer at 500 MHz and 125 MHz respectively for  $^1\text{H}$ -NMR analysis.

FT-IR-1600 Perkin-Elmer spectrophotometer. Mass spectrum using an Agilent Technologies 5975C Spectrometer with EI at 70 eV.

### Synthetic procedures [13-18]

#### Compound 1 (*E*)-1-(4-chlorophenyl)-N-(6-methoxybenzo[*d*]thiazol-2-yl)methanimine

A mixed solution of 4-ethoxybenzaldehyd (0.005 mol), 25 mL of ethanol, glacial acetic acid (3 drops), and 2-amino-6-methoxybenzothiazole (0.005 mol) were added in a round flask. 5 hours of reflux under room temperature. The filtration, and air-dried overnight to obtain a solid product. The yield 72%, light yellow-orange, and the melting point was 132 -134 °C; MS (ESI)  $m/z$  = 312.39 [M].

#### Compound 2 (*E*)-4-(((6-methoxybenzo[*d*]thiazol-2-yl)imino)methyl)phenol

A mixed solution of 4-hydroxybenzaldehyd (0.005 mol), 25 mL of ethanol, glacial acetic acid (3 drops), and 2-amino-6-methoxybenzothiazole (0.005 mol) were added in a round flask. 5 hours of reflux under room temperature. The filtration, and air-dried overnight to obtain a solid product. The yield 80%, light orange, and the melting point was 234-236 °C. MS (ESI)  $m/z$  = 284.33 [M].

#### Compound 3 (*E*)-5-((2-methylbenzylidene)amino)-2,3-dihydrophthalazine-1,4-dione

A mixed solution of 4-methylbenzaldehyd (0.005 mol), 25 mL of ethanol, glacial acetic acid (3 drops), and 3-aminophthalhydrazide (0.005 mol), were added to in a round flask. 5 hours of reflux under room temperature. The filtration, and air-dried overnight to obtain a solid product. The yield 77%, yellow, and the melting point was 97-99 °C. MS (ESI)  $m/z$  = 279.30 [M+1].

#### Compound 4 (*E*)-5-((2-hydroxybenzylidene)amino)-2,3-dihydrophthalazine-1,4-dione

A mixed solution of 2-hydroxybenzaldehyd (0.005 mol), 25 mL of ethanol, glacial acetic acid (3 drops), and 3-aminophthalhydrazide (0.005 mol), were added in a round flask. 5 hours of reflux under room temperature. The filtration, and air-dried overnight to obtain a solid product. The yield 80%, yellow, and the melting point was 111-113 °C. MS (ESI)  $m/z$  = 281.27 [M+1].

### Anticancer method

The compounds' anticancer activity was evaluated using MDA-MB-231 cancer cells. 96-well plate of  $1 \times 10^4$  cells/well was incubated overnight in RPMI-1640 media with 10% fetal bovine serum and 1% penicillin-streptomycin at 37 °C in a humidified environment with 5%  $\text{CO}_2$ . DMSO used to prepare concentrations of compounds via serially diluted to reach their final concentrations. After 48 hours of treatment, 28  $\mu\text{L}$  of MTT solution (5 mg/mL) was added to each well, and incubated for 2 hours. the formazan crystals were dissolved in 100  $\mu\text{L}$  of DMSO and use a microplate reader (BioTek ELx800) at 570 nm [19].

### Antibacterial method

Minimum inhibitory concentrations (MICs) were estimated using the diffusion method against *Escherichia coli* ATCC 11775 and *Staphylococcus aureus* ATCC 12600. In brief, applied a different concentration to each Petri dish (7 mm diameter holes in the agar gel spaced 20 mm apart). The Petri plates were incubated for 24 hours at  $36 \pm 1$  °C in aerobic conditions. Then, the growth of bacterial was monitored to determine the MIC values [20].

### Antifungal method


A standardized  $10^6$  conidia/mL by sterile saline solution (0.85%) of fungal suspension (*Candida albicans*), and 100  $\mu$ L fungal suspension was added to each Petri dish. 10 minutes later, different concentrations of compounds were prepared in 6-mm diameter holes. 70 % Dimethyl sulfoxide (DMSO) as positive control, and the fungicide tebuconazole (TEB) (Folicur 20EC) was employed at 0.1%. The plates were incubated at  $28 \pm 2$  °C, and the experiment repeated three times. After 72 hours, we measured the diameter of inhibition, and the zones of inhibition were estimated [21].

### Statistical analysis


The  $IC_{50}$  is calculated using the excel file's amount response curve. All absorbances at 570 nm are recorded for each concentration. The absorbance values are used to calculate the percentage of viability for each concentration. Next, the standard deviation and average viability are calculated.  $IC_{50}$  was calculated by replacing y in the equation with 50, which represents 50% viability, and computing the x value at y=50 to determine  $IC_{50}$  concentration

## RESULTS AND DISCUSSION


The Schiff bases derivatives (compound **1** [(E)-1-(4-chlorophenyl)-N-(6-methoxybenzo[d]thiazol-2-yl)methanimine], compound **2** [(E)-4-(((6-methoxybenzo[d]thiazol-2-yl)imino)methyl)phenol], compound **3** [(E)-5-((2-methylbenzylidene)amino)-2,3-dihydrophthalazine-1,4-dione], and compound **4** [(E)-5-((2-hydroxybenzylidene)amino)-2,3-dihydrophthalazine-1,4-dione]) were synthesized by condensation of 4-ethoxybenzaldehyd, 4-hydroxybenzaldehyd, 4-methylbenzaldehyd, and 2-hydroxybenzaldehyd with 2-amino - 6-methoxybenzothiazole and 3 - aminophthalhydrazide, as shown in **Scheme 1-4**. FT-IR,  $^1H$ -NMR, and Mass spectrum were used to identify the right chemical structure of the Schiff bases.




**Scheme 1.** The synthesis reaction of compound 1.



**Scheme 2.** The synthesis reaction of compound 2.




**Scheme 3.** The synthesis reaction of compound 3.



**Scheme 4.** The synthesis reaction of compound 4.

**Figure 1**, showed FT-IR bands of the compound 1 (HC=N stretching ( $1598.20\text{ cm}^{-1}$ ), C-H aromatic ( $3000.29\text{ cm}^{-1}$ ), S-H stretching ( $2366.27\text{ cm}^{-1}$ ), N-H stretching ( $3389.88\text{ cm}^{-1}$ ), O-CH<sub>3</sub> stretching ( $1420.41\text{ cm}^{-1}$ ), CH<sub>3</sub> stretching ( $2926.15\text{ cm}^{-1}$ ), O-C<sub>2</sub>H<sub>5</sub> ( $2850.58\text{ cm}^{-1}$ ) stretching, and C=C stretching ( $1558.89\text{ cm}^{-1}$ ). **Figure 2**, showed <sup>1</sup>H-NMR analysis of compound 1, (DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  (ppm), 2.5; s, 1H, CH=N, 9; m, Ar-H, 6.7 – 8; s, 3H, O-CH<sub>3</sub>, 3.8; s, 3H, CH<sub>3</sub>, 1.2; s, 2H, O-CH<sub>2</sub>, 3.89. **Figure 3**, showed the molecular weight of compound 1 is 312.39.



**Figure 1.** FT-IR analysis of compound 1




 Figure 2.  $^1\text{H}$ -NMR analysis for compound 1


Figure 3. Mass spectrum analysis for compound 1

**Figure 4**, showed FT-IR bands of the compound 2 (HC=N stretching ( $1601.94\text{ cm}^{-1}$ ), C-H aromatic ( $2924.73\text{ cm}^{-1}$ ), S-H stretching ( $2362.43\text{ cm}^{-1}$ ), N-H stretching ( $3387.83\text{ cm}^{-1}$ ), O-CH<sub>3</sub> stretching ( $1462.36\text{ cm}^{-1}$ ), O-H ( $3255.55\text{ cm}^{-1}$ ) stretching, and C=C stretching ( $1516.08\text{ cm}^{-1}$ ). **Figure 5**, showed  $^1\text{H}$ -NMR for compound 2, (DMSO- $d_6$ , 400 MHz)  $\delta$  (ppm), 2.5; s, 1H, CH=N, 9.8; m, Ar-H, 6.8 – 7.9; s, 3H, O-CH<sub>3</sub>, 3.8; O-H, 10.9. **Figure 6**, showed the molecular weight of compound 1 is 284.33.




Figure 4. FT-IR analysis of compound 2.




Figure 5. H-NMR analysis of compound 2.




Figure 6. Mass spectrum analysis for compound 2.






Figure 7. FT-IR analysis of compound 3





**Figure 8.**  $^1\text{H}$ -NMR analysis for compound 3.

**Figure 7**, showed FT-IR bands of the compound 3 (HC=N stretching ( $1599.62\text{ cm}^{-1}$ ), C-H aromatic ( $3056.62\text{ cm}^{-1}$ ), C=O stretching ( $1660.87\text{ cm}^{-1}$ ), N-H stretching ( $3262.82\text{ cm}^{-1}$ ), CH<sub>3</sub> stretching ( $1950.54\text{ cm}^{-1}$ ), and C=C stretching ( $1545.86\text{ cm}^{-1}$ ). **Figure 8**, showed <sup>1</sup>H-NMR analysis for compound 3 (DMSO-d<sub>6</sub>, 400 MHz)  $\delta$  (ppm), 2.5; s, 1H, CH=N, 9.6; m, Ar-H, 6.1 – 7.6; s, 3H, N-H, 1.9. **Figure 9**, showed the molecular weight of compound 3 is 279.30.



**Figure 9.** FT-IR analysis of compound 4.




Figure 10. <sup>1</sup>H-NMR analysis for compound 4.

Figure 9, showed FT-IR bands of the compound 4 (HC=N stretching (1598.94 cm<sup>-1</sup>), C-H aromatic (3056.04 cm<sup>-1</sup>), C=O stretching (1661.16 cm<sup>-1</sup>), N-H stretching (3262.46 cm<sup>-1</sup>), O-H stretching (3570.65 cm<sup>-1</sup>), and C=C stretching (3570.65 cm<sup>-1</sup>). Figure 10, showed <sup>1</sup>H-NMR for compound 4 (DMSO-d<sub>6</sub>, 400 MHz) δ (ppm), 2.5; s, 1H, CH=N, 9; m, Ar-H, 7.1 – 7.6 ; s, 3H, N-H, 6.7; s, 1H, O-H, 9.6. Figure 11, showed the molecular weight of compound 4 is 281.27.




Figure 11. Mass spectrum analysis of compound 4.

To enhance the biological functions of these compounds, the anti-breast cancer activity was examined via MTT assay and estimated  $IC_{50}$  values against MDA-MB-231 cancer cells [22]. Compound 1 has  $IC_{50}$ =165.7  $\mu$ g/ml, compound 2 has  $IC_{50}$ =224.9  $\mu$ g/ml, compound 3 has  $IC_{50}$ =582.2  $\mu$ g/ml, and compound 4 has  $IC_{50}$ =5212.9  $\mu$ g/ml, as shown **Table 1**. The compound 1 has lower  $IC_{50}$  value which can be develop for further future investigations.

**Table 1.** Anti-breast cancer activity ( $IC_{50}$  value) for compounds (1-4).

Symbol	$IC_{50}$ value ( $\mu$ g/ml)
Compound 1	165.7
Compound 2	224.9
Compound 3	582.2
Compound 4	5212.9

**Table 2.** MIC values of compounds against *E. coli*, *S. aureus*, and *C. albicans*

Symbol	<i>E. coli</i> ATCC 11775	<i>S. aureus</i> ATCC 12600	<i>C. albicans</i> ATCC 11006
Compound 1	2.5	1.25	0.625
Compound 2	2.5	1.25	0.625
Compound 3	2.5	2.5	0.0048
Compound 4	1.25	2.5	0.0097

In **Table 2**, the antibacterial activity (MIC) was examined, compounds 1 and 2 showed MIC value = 1.25 mM against *S. aureus*, compound 4 has MIC values= 1.25 mM against *E. coli*. For *C. albicans*, compound 1 and 2 = 0.625 mM, compound 3 =0.0048 mM, and compound 3=0.0048 mM, and compound 4= 0.0097 mM, **Table 2**. These results of compounds enhanced the antifungal activity against *C. albicans*. Especially compounds 3 and 4. Which means could be develop it uses and functions with merit investigation [23].

## CONCLUSION

**Fundamental Finding :** The synthesized Schiff base compounds demonstrated notable biological activities, with compound 1 exhibiting the strongest anticancer potential, compounds 1 and 2 showing meaningful antibacterial effects, and compound 4 displaying promising antifungal activity. **Implication :** These findings highlight the chemical versatility of the synthesized derivatives and suggest that Schiff bases can serve as valuable lead structures in the development of multifunctional therapeutic agents. **Limitation:** However, the current study is limited by its reliance on preliminary biological screening without extensive mechanistic, structural-activity relationship (SAR), or in vivo validation, which restricts the generalizability of the results. **Future Research :** Further investigations should therefore include comprehensive SAR studies, computational modeling, and advanced biological evaluations—including cytotoxicity profiling, mechanistic assays, and in vivo testing—to optimize these compounds and explore new derivatives with enhanced pharmacological efficacy.

## REFERENCES

- [1] H. Li, C. Dang, X. Tai, L. Xue, Y. Meng, S. Ma, and J. Zhang, "VALD-3, a Schiff base ligand synthesized from *o*-vanillin derivatives, induces cell cycle arrest and apoptosis in breast cancer cells by inhibiting the Wnt/ $\beta$ -catenin pathway," *Sci. Rep.*, vol. 11, no. 1, p. 14985, Jul. 2021, doi: 10.1038/s41598-021-94388-x.
- [2] E. Raczuk, B. Dmochowska, J. Samaszko-Fiartek, and J. Madaj, "Different Schiff bases – Structure, importance and classification," *Molecules*, vol. 27, no. 3, p. 787, Jan. 2022, doi: 10.3390/molecules27030787.
- [3] I. Tsacheva, Z. Todorova, D. Momekova, G. Momekov, and N. Koseva, "Pharmacological activities of Schiff bases and their derivatives with low and high molecular phosphonates," *Pharmaceuticals*, vol. 16, no. 7, p. 938, 2023, doi: 10.3390/ph16070938.
- [4] M. A. Malik *et al.*, "Efficacy of novel Schiff base derivatives as antifungal compounds in combination with approved drugs against *Candida albicans*," *Med. Chem.*, vol. 15, no. 6, pp. 648–658, 2019, doi: 10.2174/1573406415666181203115957.
- [5] L. Li *et al.*, "Design, synthesis, and biological activities of aromatic gossypol Schiff base derivatives," *J. Agric. Food Chem.*, vol. 62, no. 46, pp. 11080–11088, Nov. 2014, doi: 10.1021/jf504411g.
- [6] N. Beyazit, H. S. Çakran, A. Cabir, Y. Akışcan, and C. Demetgül, "Synthesis, characterization and antioxidant activity of chitosan Schiff base derivatives bearing (–)-gossypol," *Carbohydr. Polym.*, vol. 240, p. 116333, Jul. 2020, doi: 10.1016/j.carbpol.2020.116333.
- [7] Y. Liu, L. Wang, L. Zhao, and Y. Zhang, "Structure and properties of gossypol and its derivatives – from physiological activities to drug discovery and drug design," *Nat. Prod. Rep.*, vol. 39, no. 6, pp. 1282–1304, Jun. 2022, doi: 10.1039/d1np00080b.
- [8] H. Şahal, S. Öz, S. Tekin, and E. Canpolat, "Synthesis, structural characterizations and in vitro cytotoxic activities of new sulfonamide-based Schiff base derivatives," *J. Biomol. Struct. Dyn.*, vol. 41, no. 10, pp. 4361–4367, Jul. 2023, doi: 10.1080/07391102.2022.2067237.
- [9] L. Li *et al.*, "Novel dehydroabietylamine C-ring Schiff base derivatives: Synthesis, antiproliferative activity, DNA binding and molecular docking," *Chem. Asian J.*, vol. 20, no. 8, p. e202401451, Apr. 2025, doi: 10.1002/asia.202401451.
- [10] Z. Jamshidi, K. Abnous, R. Ghodsi, S. M. Taghdisi, and F. Hadizadeh, "Novel imidazolyl-hydroxamic acid Schiff base scaffold derivatives as histone deacetylase inhibitors: Design, synthesis, and biological assessment," *Bioorg. Chem.*, vol. 164, p. 108879, Sep. 2025, doi: 10.1016/j.bioorg.2025.108879.
- [11] Y. Dong, M. Li, Y. Hao, Y. Feng, Y. Ren, and H. Ma, "Antifungal activity, structure–activity relationship and molecular docking studies of 1,2,4-triazole Schiff base derivatives," *Chem. Biodivers.*, vol. 20, no. 3, p. e202201107, Mar. 2023, doi: 10.1002/cbdv.202201107.
- [12] T. A. Farghaly *et al.*, "The most recent compilation of reactions of enaminone derivatives with various amine derivatives to generate biologically active compounds," *Mini Rev. Med. Chem.*, vol. 24, no. 8, pp. 793–843, 2024, doi: 10.2174/1389557523666230913164038.
- [13] S. M. Ahmed, K. M. Salih, H. O. Ahmad, Z. H. Jawhar, and D. H. Hamad, "Synthesis, spectroscopic characterization and antibacterial activity of new Schiff base series derived from 4-aminoantipyrine and 2-aminobenzimidazole," *Zanco J. Med. Sci.*, vol. 23, no. 2, pp. 206–216, 2019, doi: 10.15218/zjms.2019.026.
- [14] R. Gunawan and A. B. D. Nandiyanto, "How to read and interpret  $^1\text{H}$ -NMR and  $^{13}\text{C}$ -NMR spectrums," *Indones. J. Sci. Technol.*, vol. 6, no. 2, pp. 267–298, 2021, doi: 10.17509/ijost.v6i2.34189.
- [15] L. Li, B. Song, B. S. Bhadury, Y. Zhang, D. Hu, and S. Yang, "Enantioselective synthesis of  $\beta$ -amino esters bearing a benzothiazole moiety via a Mannich-type reaction catalyzed by a cinchona alkaloid derivative," *Eur. J. Org. Chem.*, no. 25, pp. 4743–4746, 2011, doi: 10.1002/ejoc.201100351.

- [16] A. A. ALAbady and S. M. Al-Majidi, "Preparation of some new pyrazine and triazine derivatives and study of their antimicrobial and anticancer activities," *Iraqi J. Sci.*, pp. 2357–2372, 2024, doi: 10.24996/ij.s.2024.65.5.1.
- [17] Z. M. Ali, R. T. Alasadi, and Z. H. Abood, "Synthesis of Schiff bases for 3,6-diazahomoadamantanone and study of their antibacterial activity," *Latin Am. J. Pharm.*, vol. 43, no. 5, pp. 1717–1721, 2024.
- [18] D. Z. Mutlaq, A. A. A. Al-Shawi, and R. H. Al-Asadi, "Synthesis, characterization, anticancer activity, and molecular docking of novel maleimide-succinimide derivatives," *Egypt. Pharm. J.*, vol. 20, pp. 303–312, 2021, doi: 10.4103/epj.epj\_26\_21.
- [19] L. A. AbdulJabar, D. Z. Mutlaq, and A. A. A. Al-Shawi, "Synthesis of novel 2-thioxo-4-imidazolidinone derivatives and evaluation of their antibacterial and antifungal activities," *Egypt. J. Chem.*, vol. 64, no. 6, pp. 3059–3067, 2021, doi: 10.21608/ejchem.2021.66960.3442.
- [20] D. Z. Mutlaq, A. A. A. Al-Shawi, and L. A. AbdulJabar, "Antioxidant and antimicrobial activities of some novel 2-thiohydantoin derivatives," *Egypt. J. Chem.*, vol. 64, no. 3, pp. 1315–1321, 2021, doi: 10.21608/ejchem.2020.47419.2963.
- [21] H. H. Majeed and A. F. Abbas, "Synthesis, characterization and antioxidant activity of Schiff base derivatives from [6,6'-(1,4-phenylene)bis(4-(4-aminophenyl)pyrimidin)]," *J. Kufa Chem. Sci.*, vol. 3, no. 1, pp. 313–344, 2023, doi: 10.36329/jkcm/2023/v3.i1.12098.
- [22] Q. H. Hays and D. Z. Mutlaq, "Study of the anticancer and antimicrobial biological activity of a new series of thiohydantoin derivatives," *Baghdad Sci. J.*, vol. 21, no. 1, p. 0133, 2024, doi: 10.21123/bsj.2023.7978.
- [23] R. Sharma *et al.*, "Recent advancements in the synthesis and chemistry of benzo-fused nitrogen- and oxygen-based bioactive heterocycles," *Curr. Top. Med. Chem.*, vol. 21, no. 17, pp. 1538–1571, Oct. 2021, doi: 10.2174/1568026621666210715122919.

---

**\*Raed Jasim Mohammed (Coressponding Author)**

University of Basrah, Iraq

Email: [pgs.raed.jasim@uobasrah.edu.iq](mailto:pgs.raed.jasim@uobasrah.edu.iq)

**Hanan M. Ali**

University of Basrah, Iraq

Email: [hanan.murtada@uobasrah.edu.iq](mailto:hanan.murtada@uobasrah.edu.iq)

---